Global Antibody Production Market to Surpass USD 41.2 Billion by 2031 Amid Growing Biologics Demand and Technological Br

Gain valuable insights into the Global Antibody Production Market with our authoritative research report. Explore industry trends, technological innovations, key players, and market dynamics

[Boston, 4 June 2025] – Clearview Market Insights (CVMI) projects that the global antibody production market will grow from USD 18.1 billion in 2024 to USD 41.2 billion by 2031, achieving a robust compound annual growth rate (CAGR) of 12.6 percent. This expansion is driven by the increasing demand for monoclonal antibodies (mAbs), rapid biologics development pipelines, and ongoing innovation in cell-line engineering as well as continuous manufacturing.

“Antibodies have become foundational to modern medicine—from targeted cancer therapy to next-generation diagnostics,” said Dr. Ravi Chandra, lead biomanufacturing analyst at CVMI. “What was once a lab-scale tool has now matured into a multibillion-dollar industrial backbone supporting personalized healthcare, pandemic response, and global biosimilar growth.”

Request Sample @ https://clearviewmarketinsights.com/report-details/global-antibody-production-market/

Key Numbers

  • 2024 Market Value: USD 18.1 billion
  • 2031 Market Value: USD 41.2 billion
  • Seven-Year CAGR: 12.6 percent
  • Therapeutic Applications Share (2024): 53%
  • North America Market Share: 38%

Market Drivers

  • Rising Biologic Therapies
  • Contract Manufacturing Demand
  • Technological Advancements
  • Global Health Preparedness
  • Government Incentives

Company Highlights

  • Lonza launched Ibex® Design, reducing the timelines for clinical-scale antibody production by 40 percent.
  • Samsung Biologics has opened its fourth plant in Incheon, thereby doubling its antibody production capacity.
  • WuXi Biologics commenced development of a mega-facility in Singapore with modular POD-based architecture.
  • Thermo Fisher Scientific strengthened its biologics CDMO business through the acquisition of Belgium-based Henogen.

Regional Insights

  • North America: Dominates the market with advanced CDMO infrastructure and high biologic drug consumption.
  • Asia-Pacific: Fastest-growing region; China and India are scaling domestic production through government grants and tech transfers.
  • Europe: Hosts a strong biosimilar manufacturing base.
  • Latin America & MEA: Emerging interest in local antibody fill-finish and diagnostic assay development.

Technology Trends

  • AI-driven Bioprocessing
  • Modular Biomanufacturing
  • Cell-Line Optimization
  • Single-Use Systems

Milestones (2024–2025)

Quarter

Event

Impact

Q1 2024

Lonza launches Ibex® Design

40% faster process development cycle

Q2 2024

Samsung Biologics opens new facility

Global antibody production capacity up 25%

Q3 2024

Thermo Fisher expands CDMO services

Strengthens diagnostics-focused antibody supply

Q1 2025

WuXi Biologics breaks ground in Singapore

Modular bioproduction model enters APAC market

For more insights, visit https://clearviewmarketinsights.com/report-store  

 

About Clearview Market Insights

Clearview Market Insights is a global research and consulting firm that delivers forward-looking intelligence across more than 100 healthcare, biotechnology, and pharmaceutical markets. Our analysts synthesize real-time data, executive insights, and strategic models to support decision-making at the highest levels.

 

Media contact:

Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369

 


Bhavanik nagapuri

125 Blog posting

Komentar